Role of cytokines in the metabolic response to stress

Area of Science:

• Immunology
• Pathophysiology
• Pharmacology

Background:

• Clinical trials targeting cytokine inhibitors for sepsis and systemic inflammatory response syndromes (SIRS) have yielded disappointing results, failing to validate preclinical observations.
• Despite trial failures, advancements in understanding sepsis pathogenesis and inflammatory signaling pathways have emerged.

Purpose of the Study:

• To explore novel therapeutic opportunities for cytokine and anticytokine therapies in sepsis and SIRS.
• To leverage new knowledge of proinflammatory cytokine signal transduction pathways for treatment development.

Main Methods:

• Review of current understanding of sepsis and SIRS pathogenesis.
• Analysis of nuclear factor kappa B (NF-κB) signaling in inflammation-induced apoptosis.
• Evaluation of potential therapeutic targets within cytokine signaling cascades.

Main Results:

• Preclinical findings for cytokine inhibitors in sepsis and SIRS have not translated to clinical efficacy.
• Understanding of nuclear factor kappa B (NF-κB) and inflammation-induced apoptosis pathways offers new therapeutic avenues.
• Despite past setbacks, cytokine and anticytokine therapies remain a focus for future treatment development.

Conclusions:

• Past clinical trials with cytokine inhibitors in sepsis and SIRS were unsuccessful.
• Emerging understanding of inflammatory pathways, including NF-κB and apoptosis, presents new therapeutic opportunities.
• Further research into cytokine and anticytokine therapies is warranted based on improved pathogenetic insights.